Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

190 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer.
Kaufman PA, Wildiers H, Freyer G, Kemeny M, Gonçalves A, Jerusalem G, Stopeck A, Vrindavanam N, Dalenc F, Nanayakkara N, Wu B, Pickett CA. Kaufman PA, et al. Among authors: nanayakkara n. Clin Breast Cancer. 2019 Feb;19(1):47-57. doi: 10.1016/j.clbc.2018.09.012. Epub 2018 Oct 9. Clin Breast Cancer. 2019. PMID: 30420181 Clinical Trial.
A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.
Vergote I, Schilder RJ, Pippitt CH Jr, Wong S, Gordon AN, Scudder S, Kridelka F, Dirix L, Leach JW, Ananda S, Nanayakkara N, Melara R, Bass MB, Litten J, Adewoye H, Wenham RM. Vergote I, et al. Among authors: nanayakkara n. Gynecol Oncol. 2014 Oct;135(1):25-33. doi: 10.1016/j.ygyno.2014.07.003. Epub 2014 Jul 11. Gynecol Oncol. 2014. PMID: 25019569 Free article. Clinical Trial.
Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer.
Eatock MM, Tebbutt NC, Bampton CL, Strickland AH, Valladares-Ayerbes M, Swieboda-Sadlej A, Van Cutsem E, Nanayakkara N, Sun YN, Zhong ZD, Bass MB, Adewoye AH, Bodoky G. Eatock MM, et al. Among authors: nanayakkara n. Ann Oncol. 2013 Mar;24(3):710-8. doi: 10.1093/annonc/mds502. Epub 2012 Oct 28. Ann Oncol. 2013. PMID: 23108953 Free article. Clinical Trial.
Correction: Tubulointerstitial nephropathy is the predominant finding in men in a review of more than 3000 renal biopsies over a 10-year period from Sri Lanka.
Pett J, Linhart C, Osborne N, Morrell S, Fahim M, Knight J, Premaranthne S, Wazil AWM, Ratnatunga N, Wijethunga S, Thalgahagoda S, Endre Z, Taylor R, Nanayakkara N. Pett J, et al. Among authors: nanayakkara n. BMC Nephrol. 2024 Oct 28;25(1):384. doi: 10.1186/s12882-024-03785-7. BMC Nephrol. 2024. PMID: 39468498 Free PMC article. No abstract available.
Tubulointerstitial nephropathy is the predominant finding in men in a review of more than 3000 renal biopsies over a 10-year period from Sri Lanka.
Pett J, Linhart C, Osborne N, Morrell S, Fahim M, Knight J, Premaranthne S, Wazil AWM, Ratnatunga N, Wijethunga S, Thalgahagoda S, Endre Z, Taylor R, Nanayakkara N. Pett J, et al. Among authors: nanayakkara n. BMC Nephrol. 2024 Sep 6;25(1):295. doi: 10.1186/s12882-024-03731-7. BMC Nephrol. 2024. PMID: 39243033 Free PMC article.
190 results